Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Finished Goods (2016 - 2025)

Guided Therapeutics' Finished Goods history spans 15 years, with the latest figure at $818000.0 for Q1 2025.

  • On a quarterly basis, Finished Goods rose 1759.09% to $818000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $818000.0, a 1759.09% increase, with the full-year FY2024 number at $818000.0, up 1759.09% from a year prior.
  • Finished Goods hit $818000.0 in Q1 2025 for Guided Therapeutics, roughly flat from $818000.0 in the prior quarter.
  • Over the last five years, Finished Goods for GTHP hit a ceiling of $818000.0 in Q4 2022 and a floor of $32000.0 in Q1 2022.
  • Historically, Finished Goods has averaged $486588.2 across 5 years, with a median of $758000.0 in 2021.
  • Biggest five-year swings in Finished Goods: crashed 96.01% in 2021 and later soared 2456.25% in 2023.
  • Tracing GTHP's Finished Goods over 5 years: stood at $785000.0 in 2021, then increased by 4.2% to $818000.0 in 2022, then plummeted by 94.62% to $44000.0 in 2023, then surged by 1759.09% to $818000.0 in 2024, then changed by 0.0% to $818000.0 in 2025.
  • Business Quant data shows Finished Goods for GTHP at $818000.0 in Q1 2025, $818000.0 in Q4 2024, and $818000.0 in Q3 2024.